Interim Report January – March 2024
Best quarter for enzyme business in analytics and stronger cash position January – March 2024 · Net sales totaled SEK 40,057 (71,276) thousand, with a growth rate of -44%. Adjusted for currency effects, the decrease is -44%. Organic growth adjusted for license revenue is 0.4%, and 0.5% when also adjusted for currency effects. · Operating profit before depreciation and amortization (EBITDA) totaled SEK 18,568 (45,089) thousand. Adjusted for license revenue and related costs, EBITDA is SEK 8,440 (6,223) thousand. · Operating profit (EBIT) totaled SEK 15,833 (43,399) thousand.